Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04021108 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L)
A Phase 2 study of Gastroesophageal Adenocarcinoma, sponsored by Weill Medical College of Cornell University.
- Active
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 5
- Study locations
NCT04021108 is a Phase 2 study of Gastroesophageal Adenocarcinoma that is active but no longer recruiting, run by Weill Medical College of Cornell University. The registered enrollment target is 80 participants, below the 141-participant average among 8 other Gastroesophageal Adenocarcinoma trials with a reported enrollment target (43% lower). The trial reports 5 study locations across 4 states.
The verdict
NCT04021108, a Phase 2 study of Gastroesophageal Adenocarcinoma, is active but no longer recruiting, sponsored by Weill Medical College of Cornell University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a randomized phase II study examining nivolumab alone versus radiation therapy with nivolumab in subjects who did not have disease progression to initial therapy with the combination of FOLFOX and Nivolumab.
Conditions Studied
Interventions
- DRUG Nivolumab 240 MG
Study Locations (5)
New York
- Roswell Park Cancer Center - Buffalo
- Weill Cornell Medicine - New York
Florida
- Moffitt Cancer Center - Tampa
Missouri
- Washington University School of Medicine - St Louis
Nebraska
- University of Nebraska - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2019-07-22 |
| Est. Completion | 2026-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04021108
The ClinicalTrials.gov registry entry for NCT04021108 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 141-participant average among 8 other Gastroesophageal Adenocarcinoma trials with a reported enrollment target (43% lower). The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Gastroesophageal Adenocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which Nivolumab 240 MG is the first listed.
NCT04021108 reports 5 study locations spanning 4 distinct geographic areas - top geographies include New York, Florida, Missouri.
Frequently Asked Questions
What is clinical trial NCT04021108 about?
NCT04021108 is a clinical study titled "Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L)". This is a randomized phase II study examining nivolumab alone versus radiation therapy with nivolumab in subjects who did not have disease progression to initial therapy with the combination of FOLFOX and Nivolumab.
What is the current status of trial NCT04021108?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2019-07-22. Estimated completion is 2026-06.
What conditions does trial NCT04021108 study?
This clinical trial studies the following conditions: Gastroesophageal Adenocarcinoma.
What interventions are being tested in trial NCT04021108?
The interventions under investigation include: Nivolumab 240 MG (DRUG).
Who is sponsoring clinical trial NCT04021108?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04021108 being conducted?
This trial has 5 study locations across Florida, Missouri, Nebraska, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastroesophageal Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
RECRUITING · Phase 2
-
Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels
RECRUITING · Phase 2
-
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
RECRUITING · Phase 1
-
Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease
RECRUITING · Phase 1
-
Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)
RECRUITING · Phase 1
-
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.